Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension.

Pan XD, Zeng ZH, Liang LY, Luo JD, Xiao AY, Lai Q, Wen YH, Lu DF, Wang W, He ZC, He WK.

Clin Exp Hypertens. 2011;33(8):558-64. doi: 10.3109/10641963.2011.577486. Epub 2011 Sep 29.

PMID:
21957976
2.

Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension.

Ivanova OV, Fomicheva OA, Sergakova LM, Chernova NA, Rogoza AN, Karpov YA.

J Int Med Res. 2005;33 Suppl 1:21A-29A.

PMID:
16222897
3.

Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan.

Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G.

Int J Cardiol. 2004 Dec;97(3):383-8.

PMID:
15561322
4.

Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension.

Mattioli AV, Bonatti S, Monopoli D, Zennaro M, Mattioli G.

Blood Press. 2005;14(5):273-8.

PMID:
16257872
5.
6.

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.

Galzerano D, Tammaro P, del Viscovo L, Lama D, Galzerano A, Breglio R, Tuccillo B, Paolisso G, Capogrosso P.

Am J Hypertens. 2005 Dec;18(12 Pt 1):1563-9.

PMID:
16364826
7.

[Effects of heart rate variability and smoothness index on the reversal of hypertensive left ventricular hypertrophy].

Wang HB, Shi Q, Zhang C.

Zhonghua Yi Xue Za Zhi. 2011 Mar 29;91(12):832-5. Chinese.

PMID:
21600164
8.

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators.

Circulation. 2009 Feb 3;119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214. Epub 2009 Jan 19.

9.

Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin-treated hypertensive hypercholesterolemic patients.

Cicero AF, Veronesi M, Prandin MG, Di Gregori V, Ambrosioni E, Borghi C.

Fundam Clin Pharmacol. 2009 Oct;23(5):583-8. doi: 10.1111/j.1472-8206.2009.00719.x. Epub 2009 Jun 25.

PMID:
19555395
10.

[The effect of hypotensive drugs on left ventricular mass and diastolic function].

Spring A, Haczyński J, Jołda-Mydłowska B, Witkowska M.

Pol Arch Med Wewn. 1995 Jul;94(1):47-58. Polish.

PMID:
8524699
11.

Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.

Littlejohn TW 3rd, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W; study investigators.

Postgrad Med. 2009 Mar;121(2):5-14. doi: 10.3810/pgm.2009.03.1972.

PMID:
19332958
12.

Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy.

Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Carpi A, Antonelli A, Santoro G.

Biomed Pharmacother. 2010 Oct;64(8):516-20. doi: 10.1016/j.biopha.2009.09.016. Epub 2009 Dec 9.

PMID:
20044234
13.

A comparison study of the echocardiographic changes in hypertensive patients treated with telmisartan vs. enalapril.

Hadi NR, Abdulzahra MS, Al-Huseini LM, Al-Aubaidy HA.

Int J Cardiol. 2017 Mar 1;230:269-274. doi: 10.1016/j.ijcard.2016.12.127. Epub 2016 Dec 22.

PMID:
28041700
14.

Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan.

Fountoulaki K, Dimopoulos V, Giannakoulis J, Zintzaras E, Triposkiadis F.

Am J Hypertens. 2005 Feb;18(2 Pt 1):171-7.

PMID:
15752943
15.

Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy.

Hinoi T, Tomohiro Y, Kajiwara S, Matsuo S, Fujimoto Y, Yamamoto S, Shichijo T, Ono T.

Hypertens Res. 2008 Apr;31(4):615-22. doi: 10.1291/hypres.31.615.

PMID:
18633172
16.

Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging.

Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, Oki T.

J Hypertens. 2009 Sep;27(9):1892-9. doi: 10.1097/HJH.0b013e32832d8785.

PMID:
19506525
18.
19.

Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.

Grandi AM, Solbiati F, Laurita E, Maresca AM, Nicolini E, Marchesi C, Gianni M, Guasti L, Venco A.

Am J Hypertens. 2008 Feb;21(2):231-7. doi: 10.1038/ajh.2007.47. Epub 2008 Jan 3.

PMID:
18174880
20.

Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.

Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A; CATCH investigators.

J Hypertens. 2002 Nov;20(11):2293-300.

PMID:
12409969

Supplemental Content

Support Center